Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open, Multinational, Multicentre,2-Part Study In Spontaneously Breathing Preterm Neonates With Mild To Moderate Respiratory Distress Syndrome (RDS) To Investigate The Safety, Tolerability And Efficacy Of Inhaled Nebulised Poractant Alfa (Porcine Surfactant, Curosurf) In Comparison With Nasal Continuous Positive Airway Pressure (nCPAP) Alone

Trial Profile

A Randomized, Open, Multinational, Multicentre,2-Part Study In Spontaneously Breathing Preterm Neonates With Mild To Moderate Respiratory Distress Syndrome (RDS) To Investigate The Safety, Tolerability And Efficacy Of Inhaled Nebulised Poractant Alfa (Porcine Surfactant, Curosurf) In Comparison With Nasal Continuous Positive Airway Pressure (nCPAP) Alone

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Poractant alfa (Primary)
  • Indications Respiratory distress syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Chiesi Farmaceutici
  • Most Recent Events

    • 04 Mar 2022 Primary endpoint (Percentage of neonates with respiratory failure) has not been met according to the results published in the Journal of Pediatrics
    • 04 Mar 2022 Results published in the Journal of Pediatrics
    • 07 Jun 2020 This trial is discontinued in Hungary, UK and France (Global End Date: 05 May 2020), according to European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top